Table 2.
The risk of all-cause dementia between cilostazol cohort and comparison cohort
| Case no. | % | cHR (95% CI) | p-value | aHR (95% CI) | p-value | |
|---|---|---|---|---|---|---|
| Comparison cohort (n = 6861) | 586 | 8.5 | Ref. | Ref. | ||
| Cilostazol cohort (n = 2287) | 109 | 4.8 | 0.77 (0.63–0.95) | 0.015 | 0.75 (0.61–0.92) | 0.006 |
| <86 DDDs (N= 763) | 40 | 5.2 | 0.90 (0.65–1.24) | 0.527 | 0.88 (0.64–1.22) | 0.448 |
| 86–217 DDDs (N= 762) | 38 | 5.0 | 0.91 (0.65–1.26) | 0.567 | 0.92 (0.66–1.27) | 0.602 |
| >217 DDDs (N= 762) | 31 | 4.1 | 0.57 (0.40–0.82) | 0.002 | 0.53 (0.37–0.76) | 0.001 |
| p for trend | 0.003 | 0.001 |
Adjusted for age, sex, all comorbidities, and history of medication. cHR = crude hazard ratio; CI = confidence interval; aHR = adjusted hazard ratio; DDD = defined daily dose.